People · Operator
Named in public records as an officer, director or promoter · active 2009–2014 · Pharmaceuticals, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Sunesis Pharmaceuticals Inc | — | Pharmaceuticals | Series B | $38.5M | $969.1M | 2009 |
| NEXTWAVE PHARMACEUTICALS Inc | — | Pharmaceuticals | Series B | $27.2M | $925.9M | 2011 |
| Interleukin Genetics Inc | — | Biotechnology | Series A | $25.6M | $202.2M | 2014 |
| Aciex Therapeutics, Inc. | — | Biotechnology | Series A | $9.6M | $57.8M | 2011 |
Dayton Misfeldt at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Dayton Misfeldt on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Ed Hurwitz | 1 | 9 |
| ANAND MEHRA | 1 | 7 |
| Jake Nunn | 1 | 5 |
| Steve Elms | 1 | 4 |
| Linda Ara | 1 | 3 |
| Gaurav Aggarwal | 1 | 3 |
| JAMES W. YOUNG | 1 | 3 |
| Lionel Carnot | 1 | 3 |
| Jay Shepard | 1 | 3 |
| Homer L. Pearce | 1 | 3 |
| Matthew K. Fust | 1 | 3 |
| Eric H. Bjerkholt | 1 | 2 |
| William C. Mills, III | 1 | 2 |
| James Weaver | 1 | 2 |
| Robert Casale | 1 | 2 |
| Frank Kung | 1 | 2 |
| Lewis H. Bender | 1 | 2 |
| Michael Burdick | 1 | 2 |
| Stephen DiPalma | 1 | 2 |
| Thomas H. Curran | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.